Dare Bioscience Forecasts $0.38M Q4 Revenue, Sees 690% Price Upside
Dare Bioscience forecasts Q4 2025 revenue of $0.38 million and a loss of $0.43 per share, with full-year 2025 projections matching $0.38 million in revenue and a $1.65 per-share loss. Analysts set a $10.75 one-year price target implying 690% upside and maintain an Outperform rating.
1. Q4 and Full-Year 2025 Estimates
Dare Bioscience is projected to report $0.38 million in revenue and a loss of $0.43 per share for Q4 2025, matching full-year revenue consensus of $0.38 million with a total EPS loss of $1.65.
2. 2026 Estimate Trends
Over the past 90 days, revenue forecasts for 2026 have held steady at $330 million and EPS estimates at -$0.35 per share, indicating no recent analyst revisions to growth projections.
3. Q3 2025 Actual Results
In Q3 2025, the company posted zero revenue, missing the $0.01 million consensus by 80%, yet delivered an EPS loss of $0.28, beating the -$0.385 forecast by 27%.
4. Analyst Price Targets and Ratings
Four analysts set an average one-year price target of $10.75, suggesting 690% upside from the current $1.36 price, and maintain an average brokerage recommendation of 2.0, signaling Outperform.